{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T19:48:42Z","timestamp":1777060122099,"version":"3.51.4"},"reference-count":45,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2021,1,1]]},"DOI":"10.1080\/13696998.2021.1974763","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T07:39:06Z","timestamp":1630481946000},"page":"1124-1133","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer"],"prefix":"10.1080","volume":"24","author":[{"given":"Caitlin","family":"Smare","sequence":"first","affiliation":[{"name":"HEOR, Parexel International, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran","family":"Dave","sequence":"additional","affiliation":[{"name":"HEOR, Parexel International, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariadna","family":"Juarez-Garcia","sequence":"additional","affiliation":[{"name":"Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, Uxbridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranav","family":"Abraham","sequence":"additional","affiliation":[{"name":"Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Penrod","sequence":"additional","affiliation":[{"name":"Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Ross","family":"Camidge","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, University of Colorado Denver School of Medicine, Denver, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"CIT0001","unstructured":"GLOBOCAN. New global cancer data: GLOBOCAN 2018; 2018. [updated 12 Sept 2018; cited 11 August 2020]; Available from: https:\/\/www.uicc.org\/new-global-cancer-data-globocan-2018"},{"issue":"12","key":"CIT0002","volume":"17","author":"Gazdar AF","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-9-1096"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28505"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.6.1794"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt178"},{"key":"CIT0007","unstructured":"US Food and Drug Administration. FDA grants nivolumab accelerated approval for third-line treatment of metastatic small cell lung cancer 2018. [updated August 16, 2018; cited 11 August 2020]. Available from: https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm617370.htm"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30098-5"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.10.003"},{"key":"CIT0010","unstructured":"National Comprehensive Cancer Network (NCCN), Small cell lung cancer. Version 2; 2021."},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0079"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00845-x"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-019-00513-3"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.602185"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v070.i08"},{"key":"CIT0017","unstructured":"CheckMate 032 clinical trial report (data on file). Princeton (NJ): Bristol Myers Squibb; 2018."},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2020-0134"},{"key":"CIT0019","unstructured":"Flatiron Heath, Flatiron health records (data on file). Princeton (NJ): Bristol Myers Squibb; 2018."},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.3998"},{"key":"CIT0021","unstructured":"Centers for Medicare and Medicaid Services. 2018. CMS physician fee schedule 2018 [cited 11 August 2020]. Available from: https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/PhysicianFeeSched\/"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1177\/0269216315596505"},{"key":"CIT0023","unstructured":"Latimer NR. NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials \u2013 extrapolation with patient-level data. Report by the Decision Support Unit; 2013. [cited 2020 August 11]. Available from: http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf"},{"key":"CIT0024","unstructured":"CheckMate 003 clinical trial report (data on file). Princeton (NJ): Bristol Myers Squibb; 2018."},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.5392"},{"key":"CIT0027","volume-title":"The impact of landmark response on overall survival: implications for the economic evaluation of immune-therapy (I-O) treatment in small cell lung cancer (SCLC)","author":"Santi I"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00806-4"},{"key":"CIT0029","doi-asserted-by":"crossref","unstructured":"Santi I, Johal S, Yuan Y, et\u00a0al. The impact of response at a landmark on overall survival: implications for the economic evaluation of the value of immune-oncology (I-O) treatment in non-small cell lung cancer (NSCLC). Value Health. 2018:21(suppl1):S211.","DOI":"10.1016\/j.jval.2018.04.1436"},{"key":"CIT0030","unstructured":"National Institute for Health and Care Excellence. Nivolumab for previously treated squamous non-small-cell lung cancer. Technology appraisal guidance [TA483]; 2017. [cited 2020 August 11]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta483\/chapter\/4-Committee-discussion"},{"key":"#cr-split#-CIT0031.1","unstructured":"National Institute for Health and Care Excellence. Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy. Technology approasial guidance [TA428]. 2017. [updated 2017 September 12"},{"key":"#cr-split#-CIT0031.2","unstructured":"cited 2020 August 11]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta428."},{"key":"#cr-split#-CIT0032.1","unstructured":"National Institute for Health and Care Excellence. Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer. Technology appraisal guidance [TA584]. 2019. [updated 2019 5 June"},{"key":"#cr-split#-CIT0032.2","unstructured":"cited March 2021]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta584\/chapter\/1-Recommendations"},{"key":"CIT0033","unstructured":"National Institute for Health and Care Excellence. Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy. Technology appraisal guidance [TA520]. 2018. [updated 16 May 2018; cited March 2021]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta520\/chapter\/1-Recommendations."},{"key":"CIT0034","unstructured":"National Institute for Health and Care Excellence. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer. Technology appraisal guidance [TA531]. 2018. [updated 18 July 2018; cited March 2021]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta531\/chapter\/1-Recommendation."},{"key":"CIT0035","unstructured":"National Institute for Health and Care Excellence. Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer. Technology appraisal guidance [TA600]. 2019. [updated 11 September 2019; cited March 2021]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta600\/chapter\/1-Recommendations."},{"key":"CIT0036","unstructured":"National Institute for Health and Care Excellence. Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer. Technology appraisal guidance [TA683]. 2021. [updated 10 March 2021; cited March 2021]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta683\/chapter\/1-Recommendations."},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.3386\/w13333"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-2-90"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2012.0174"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0b013e3182a78fd8"},{"key":"CIT0041","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) cancer statistics review 1975-2012. [cited 2020 August 11]. Available from: https:\/\/seer.cancer.gov\/archive\/csr\/1975_2012\/results_merged\/topic_historical_mort_trends.pdf"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-017-0045-0"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2021.1974763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T12:44:59Z","timestamp":1641386699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2021.1974763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"alternative-id":["10.1080\/13696998.2021.1974763"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2021.1974763","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-09-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}